Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?
Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders? Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 29, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--UTZ, NEUP, SAFT, and NRIM PR Newswire NEW YORK, July 29, 2026 NEW YORK, July 29, 2026 /PRNewswire...
PR Newswire
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. Upon closing of the proposed transaction, Neuphoria shareholders will own 14.5% of the combined company.Halper Sadeh encourages Neuphoria shareholders...
Business Wire
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) PR Newswire NEW YORK, July 24, 2026 NEW YORK, July 24, 2026...
PR Newswire
Scancell Makes Bold U.S. Push with Game-Changing Neuphoria Deal
Scancell Holdings (AIM:SCLP) and Neuphoria Therapeutics (NASDAQ:NEUP) have unveiled a transformative all-share merger designed to position the combined company for its next stage of clinical and commercial growth. Upon closing, the combined business will operate under the Scancell name and intends to list on NASDAQ under the proposed ticker SCLT, while maintaining Scancell's existing AIM listing. The transaction combines Scancell's late-stage immunotherapy pipeline with Neuphoria's public market platform and remaining cash resources, creating a company focused on advancing active cancer immunotherapies with expanded access to U.S. capital markets.
24-7 Market News
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition
Neuphoria also added that it received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP earlier this week to acquire all of the outstanding shares of Neuphoria that it does not already own for $5.20 per share in cash.
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes
This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.